Company intelligence / Profile preview
KYinno Biotechnology
- Ownership
- Private
- Employees
- ~130
- Development stage
- Preclinical
Overview
Kyinno Biotechnology is an active pre-clinical contract research organization founded in Beijing in 2017 with significant operations now also based out of Waltham/Boston area. The company's core expertise lies in oncology drug discovery—especially immune therapies such as bispecific/trispecfic/ADC modalities—and providing advanced custom-engineered cellular models to support pharmaceutical R&D worldwide. Their lead internal program has reached Phase II clinical trials for refractory multiple myeloma using a trispecfic format targeting BCMA/CD3/GPRC5D.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific antibodyTrispecific antibodyMonoclonal antibodyAntibody-drug conjugateBispecific T-cell engager (BiTE)Small molecule
- Industry
- Biotech
Drug pipeline
12 assets11 more assets in the full pipeline.
Beyond the preview
Go deeper on KYinno Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KYinno Biotechnology.